CX Institutional Has $22.58 Million Holdings in Eli Lilly and Company $LLY

Key Points

• CX Institutional increased its stake in Eli Lilly and Company (NYSE: LLY) by 6.4% during the second quarter, acquiring an additional 1,744 shares, bringing its total holdings to 28,967 shares valued at approximately $22.58 million.
• Several institutional investors have significantly increased their positions in Eli Lilly, including PNC Financial Services, which raised its stake by 97.5%, and GAMMA Investing, which increased its position by an astounding 103,831.6%.
• Eli Lilly reported strong earnings with an EPS of $6.31 for the last quarter, exceeding estimates and achieving a 37.6% revenue increase versus the prior year.

CX Institutional boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,967 shares of the company's stock after buying an additional 1,744 shares during the period. Eli Lilly and Company accounts for 0.8% of CX Institutional's portfolio, making the stock its 29th biggest holding. CX Institutional's holdings in Eli Lilly and Company were worth $22,580,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Hobbs Wealth Management LLC increased its holdings in Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after buying an additional 12 shares during the last quarter. Hixon Zuercher LLC grew its holdings in Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC grew its holdings in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC grew its holdings in Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners grew its holdings in Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock valued at $407,000 after purchasing an additional 13 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Leerink Partners reissued a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Finally, Cantor Fitzgerald reduced their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Stock Down 1.4%

NYSE LLY traded down $10.55 during trading on Tuesday, hitting $744.40. The stock had a trading volume of 1,395,356 shares, compared to its average volume of 4,082,222. The company has a market capitalization of $704.54 billion, a PE ratio of 48.69, a P/E/G ratio of 1.05 and a beta of 0.47. The company's 50-day moving average price is $737.49 and its two-hundred day moving average price is $769.01. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.